Lei Chen

Dr. Lei Chen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SXShumei Xiao
Shumei Xiao
LCLei Chen
Lei Chen
CZChen Zhichao
Chen Zhichao
QLQiubai Li
Qiubai Li
Extracellular vesicles (EVs) have emerged as pivotal regulators for extensive intercellular crosstalk owing to capsuled diverse bioactive substances such as proteins, nucleic acids, and lipids. Recent studies have shown that tumor-derived EVs significantly influence the bone marrow microenvironment, contributing to the progression of multiple myeloma (MM). This highlights the robust potential of EVs as a promising avenue for developing more effective and precise diagnostic and therapeutic strategies for MM. In this review, we briefly discuss the multifaceted roles of EVs in MM progression, as well as the diagnostic and therapeutic value in MM management. Specifically, we focus on the latest research progress regarding the therapeutic potential of EVs for MM, particularly tumor cell-derived EVs, as we elaborate on three main aspects: (i) EVs as therapeutic targets, including the targeted inhibition of EV biogenesis and uptake, and the possibility of eliminating tumor-derived EVs; (ii) EVs as delivery nanovectors, where we discuss the latest anti-MM candidates and potential ways to optimize therapeutic efficiency; and (iii) engineered EVs as antitumor vaccines, focusing on the use of tumor cell-derived EVs in immunotherapy. Finally, we address the prospects and challenges of harnessing the therapeutic potential of EVs in clinical transformation.

2 May 2025 in Clinical and Translational Medicine
Verified
Journal Article
Open access
YCYulin Cao
Yulin Cao
XHXuan Hu
Xuan Hu
DWDi Wu
Di Wu
YJYuxuan Jiang
Yuxuan Jiang
YYYali Yu
Yali Yu
QLQiubai Li
Qiubai Li
Background: Engineered extracellular vesicles (EVs) are emerging as a highly potential platform for targeted drug delivery in cancer therapy. Although intravenous injection is commonly used in EV treatment, there is growing interest in using microneedles (MNs) for transdermal EV delivery; however, comprehensive studies comparing the tissue distribution, safety and antitumour efficacy of these two approaches for delivering engineered EVs remain scarce.Methods: We used EVs derived from umbilical cord mesenchymal stem cells, modified with phospholipid‒polyethylene glycol‒N‐hydroxysuccinimide and conjugated with CD38 peptides (CD38‐EVs), to target myeloma cells that highly express CD38 antigen, and tested their safety and antitumour efficacy in mice with subcutaneous plasmacytoma, administrated via dissolvable transdermal MNs or intravenous injection. Flow cytometry, immunofluorescence and fluorescence molecular projection imaging analysis were employed to evaluate the distribution of CD38‐EVs at the cellular level and within living systems. Additionally, histopathological analysis and biochemical analyses were conducted to assess the antitumour effects and safety of CD38‐EVs loaded with doxorubicin (CD38‐EVs‐Dox).Results: Compared to standard EVs, CD38‐EVs exhibited enhanced uptake by CD38high tumour cells and reduced uptake by CD38‐negative non‐tumour cells in vitro. In plasmacytoma NOD/SCID mouse models, CD38‐EVs encapsulated within MNs (CD38‐EVsMNs) effectively targeted the tumour cells much more than the standard EVs encapsulated within MNs (EVsMNs) and CD38‐EVs intravenously administrated (CD38‐EVsi.v), with reduced distribution to the lungs and spleen. Additionally, CD38‐EVs‐Dox induced significantly greater cytotoxicity against the tumour cells than EVs‐Dox in vitro, and CD38‐EVs‐DoxMNs significantly reduced tumour burden compared to both EVs‐DoxMNs and CD38‐EVs‐Doxi.v, while maintaining favourable safety profiles.Conclusions: CD38‐EVs‐DoxMNs have superior efficacy and safety in treating plasmacytoma mice, compared to CD38‐EVs‐Doxi.v, providing novel insights into the potential of MNs as a platform for delivering targeted engineered EVs in tumour therapy.Highlights: Enhanced tumor targeting: CD38‐modified EVs (CD38‐EVs) showed increased uptake by CD38high tumor cells while reducing uptake by CD38‐negative non‐tumor cells. Optimized delivery: MN‐loaded CD38‐EVs targeted tumors more effectively than MN‐loaded EVs and intravenously injected CD38‐EVs, with lower lung and spleen accumulation. Superior antitumor efficacy: MN‐delivered CD38‐EVs‐Dox significantly suppressed tumor growth, outperforming intravenous CD38‐EVs‐Dox and MN‐delivered EVs‐Dox.

1 February 2025 in Carcinogenesis
Verified
Journal Article
Closed access
DLDehu Li
Dehu Li
BQBing Qiao
Bing Qiao
QCQianwen Cheng
Qianwen Cheng
LCLei Chen
Lei Chen
FZFei Zhao
Fei Zhao
CSChunyan Sun
Chunyan Sun
Macrophage migration inhibitory factor (MIF) emerged in recent years as an important cytokine with a pleiotropic spectrum of biological functions implicated in the pathogenesis of inflammatory diseases and malignancies. A growing body of research indicates that the overexpression of MIF is prevalent across a variety of solid tumors. Howbeit, there are fewer studies regarding the expression and clinical significance of serum MIF in multiple myeloma (MM) patients. In this study, we investigated the clinical significance of serum MIF in newly diagnosed MM (NDMM) patients and explored the effect of exogenous MIF on the proliferation, migration, and invasion of MM cells in vitro. Herein, our study revealed that NDMM patients exhibited markedly elevated serum MIF levels compared to healthy adults. High levels of MIF were associated with advanced International Staging System (ISS) stage and the Second Revision of the International Staging System (R2-ISS) stage. Besides, NDMM patients with high levels of MIF were prone to have a higher incidence of hypercalcemia, renal insufficiency, high tumor burden, and extramedullary lesions. Moreover, we found that serum MIF, creatinine, and lactate dehydrogenase levels were independent risk factors for predicting poor progression-free survival and overall survival in NDMM patients. Meanwhile, in vitro experiments revealed that MIF can promote the proliferation of MM cells and enhance their migration and invasion. Our study confirmed that NDMM patients with high serum MIF levels showed poor clinical characteristics and inferior prognosis. Therefore, MIF may serve as a promising biomarker in the clinical practice of MM.

1 August 2020 in Leukemia Research
Verified
Journal Article
Closed access
HHHai-Fan Huang
Hai-Fan Huang
JXJian Xu
Jian Xu
AXAo-Shuang Xu
Ao-Shuang Xu
XWXiao-Yue Wan
Xiao-Yue Wan
LCLei Chen
Lei Chen
YHYu Hu
Yu Hu

30 January 2026 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
JQJiao Qu
Jiao Qu
YLYancheng Li
Yancheng Li
CLChenchen Li
Chenchen Li
DWDi Wu
Di Wu
YCYulin Cao
Yulin Cao
LCLei Chen
Lei Chen
Background: Multiple myeloma (MM) is the second most common hematologic malignancy in adults. Owing to marked heterogeneity in pathogenesis, clinical presentation and prognosis, the 5-year survival rate remains approximately 50%. Robust and clinically actionable biomarkers are therefore urgently needed to refine risk stratification, guide therapeutic decisions and improve prognostic accuracy. ADAM17 (A Disintegrin and Metalloproteinase-17) plays a pivotal role in inflammation, tissue homeostasis and tumorigenesis. Although the research in MM was limited, the existing evidence suggests that ADAM17 may be involved in the pathological process of the disease. Methods: In this study, the serum ADAM17 concentrations of 26 MM patients at three different clinical stages (newly diagnosed, remission and progression) were detected by ELISA, and the correlation between ADAM17 concentrations and clinical parameters was analyzed. The expression levels of CD62L on bone marrow T cells of MM patients and healthy donors were compared by flow cytometry. In addition, the above findings were verified in the expanded cohort using the GEO public data set. Results: Serum ADAM17 concentrations increased progressively from remission to progression and at diagnosis. Levels aligned with DS, ISS and R-ISS staging systems and were strongly associated with renal function. Compared with healthy controls, T cells from MM patients displayed significantly reduced CD62L expression across CD3 + , CD4 + and CD8 + subsets, with the most pronounced loss on CD8 + T cells. CIBERSORT analysis revealed significantly higher bone-marrow infiltration of CD8 + T cells in patients with low versus high ADAM17 expression. Conclusion: Our data identify ADAM17 as an easily quantifiable, longitudinal biomarker that concurrently reflects tumor development stage and renal function damage in MM patients. Incorporation of ADAM17 into existing risk algorithms may enhance prognostic precision and enable earlier, patient-tailored intervention.

18 February 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CLCao Yu Lin
Cao Yu Lin
DWDi Wu
Di Wu
KZKuo Zeng
Kuo Zeng
LCLei Chen
Lei Chen
JYJianming Yu
Jianming Yu
QLQiubai Li
Qiubai Li
(1) Background: Although there are extensive data on admission co-variates and outcomes of persons with coronavirus infectious disease-2019 (COVID-19) at diverse geographic sites, there are few, if any, subject-level comparisons between sites in regions and countries. We investigated differences in hospital admission co-variates and outcomes of hospitalized people with COVID-19 between Wuhan City, China and the New York City region, USA. (2) Methods: We retrospectively analyzed clinical data on 1859 hospitalized subjects with COVID-19 in Wuhan City, China, from 20 January to 4 April 2020. Data on 5700 hospitalized subjects with COVID-19 in the New York City region, USA, from 1 March to 4 April 2020 were extracted from an article by Richardson et al. Hospital admission co-variates (epidemiological, demographic, and laboratory co-variates) and outcomes (rate of intensive care unit [ICU] admission, invasive mechanical ventilation [IMV], major organ failure and death, and length of hospital stay) were compared between the cohorts. (3) Results: Wuhan subjects were younger, more likely female, less likely to have co-morbidities and fever, more likely to have a blood lymphocyte concentration > 1 × 109/L, and less likely to have abnormal liver and cardiac function tests compared with New York subjects. There were outcomes data on all Wuhan subjects and 2634 New York subjects. Wuhan subjects had higher blood nadir median lymphocyte concentrations and longer hospitalizations, and were less likely to receive IMV, ICU hospitalization, and interventions for kidney failure. Amongst subjects not receiving IMV, those in Wuhan were less likely to die compared with New York subjects. In contrast, risk of death was similar in subjects receiving IMV at both sites. (4) Conclusions: We found different hospital admission co-variates and outcomes between hospitalized persons with COVID-19 between Wuhan City and the New York region, which should be useful developing a comprehensive global understanding of the SARS-CoV-2 pandemic and COVID-19.